2 Healthcare Stocks Wall Street Analysts Say Could Rally 60% or More

Viking Therapeutics completed enrollment in a pivotal phase 3 trial for VK2735 with a readout expected next year and plans a phase 3 start for an oral VK2735 in Q3, prompting bullish analyst price targets of $107 and $125. HCA Healthcare reported Q4 2025 same-facility admissions +2.4% YoY and revenue up nearly 7% to $19.5B, with management guiding for up to +6% revenue growth this year and citing demographic tailwinds (65+ cohort projected to reach 71.6M by 2030). Viking is viewed as a higher-risk, higher-upside biotech with above-average chances of regulatory/commercial success; HCA is characterized as a solid, long-term, buy-and-hold healthcare operator leveraging AI (Timpani) to address staffing constraints.

Analysis

VKTX’s program outcome is a classic binary that cascades beyond the stock: a clean positive readout will validate oral GLP-1/GLP-1-adjacent pathways and materially change channel economics (shifting sales from specialty clinics and injectables to primary care and retail pharmacy), compressing per-patient gross margins across incumbents and forcing faster price competition. Conversely, a setback won’t just de-rate VKTX — it will slow investor appetite for late-stage oral candidates and tighten M&A bids for similar platforms for 6–18 months as acquirers reprice development risk.

For HCA, realized AI staffing gains are the lever with the highest optionality but the longest implementation lag: even modest productivity improvements (5–7% FTE-equivalent reduction) would flow almost entirely to EBITDA within 12–24 months given current labor intensity, but regulatory, union, and EMR-integration friction could delay capture and create headline risk. The real second-order benefit is throughput improvement — shorter lengths of stay and higher bed turnover raise case-mix-adjusted revenue per facility and accelerate payback on capex and M&A of smaller systems.

The consensus underprices two risks: (1) reimbursement dynamics — payors can blunt price realization for new obesity drugs via step-therapy and prior authorization, reducing peak sales and valuations; (2) operational execution for AI benefits — hospitals with legacy workflows will capture only a fraction of projected savings in year one, making near-term margin beats binary rather than linear. Both create fertile ground for asymmetric option-based positioning rather than large directional equity bets.

Key Decisions for Investors

• Directional, defined-risk VKTX play: buy a small-sized (1–2% portfolio) 12–18 month OTM call spread on VKTX to capture a positive phase-3 readout. Rationale: limited premium at risk, asymmetric upside if market awards a biotech re-rate; main risk = binary clinical failure that loses premium.
• Relative-value hospital trade: long HCA equity (or 9–12 month LEAP calls) and short a regional hospital operator (e.g., UHS or THC) to express AI-driven margin outperformance. Timeframe 12–24 months; aim for 2:1 upside skew if HCA converts staffing gains while peers lag. Hedge with stop-loss at 8–10% to protect on macro-driven elective volume shocks.
• Volatility play around approval/M&A chatter: buy straddles on VKTX 60–90 days into expected catalyst windows (readout or NDA milestones) sized to 0.5–1% portfolio. Expect large IV repricing; profit by selling into post-catalyst volatility crush if outcome is positive and buy-side competition emerges.
• Conservative income alternative: initiate a covered-call or buy-write on HCA to collect premium while retaining core exposure to demographic tailwinds. Timeframe 6–12 months; target 4–6% annualized yield with capped upside, suitable for income-biased allocations wary of near-term execution risk.